MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The company uses iPS cells to develop treatments for diseases relating to the kidney
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Subscribe To Our Newsletter & Stay Updated
